There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Supernus Pharmaceuticals (SUPN – Research Report), Viatris (VTRS – Research Report) and Regeneron (REGN – Research Report) with bullish sentiments.
Supernus Pharmaceuticals (SUPN)
Jefferies analyst Andrew Tsai maintained a Buy rating on Supernus Pharmaceuticals yesterday and set a price target of $45.00. The company’s shares closed last Friday at $30.97, close to its 52-week low of $29.06.
According to TipRanks.com, Tsai is a 2-star analyst with an average return of
Currently, the analyst consensus on Supernus Pharmaceuticals is a Moderate Buy with an average price target of $44.00, representing a 46.5% upside. In a report issued on August 9, Piper Sandler also reiterated a Buy rating on the stock with a $43.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Viatris (VTRS)
Jefferies analyst Glen Santangelo reiterated a Buy rating on Viatris today and set a price target of $15.00. The company’s shares closed last Friday at $11.26.
According to TipRanks.com, Santangelo is a 5-star analyst with an average return of
Currently, the analyst consensus on Viatris is a Hold with an average price target of $12.25.
Regeneron (REGN)
In a report issued on August 18, Akash Tewari from Jefferies maintained a Buy rating on Regeneron, with a price target of $895.00. The company’s shares closed last Friday at $812.40, close to its 52-week high of $837.55.
According to TipRanks.com, Tewari is a 5-star analyst with an average return of
Currently, the analyst consensus on Regeneron is a Moderate Buy with an average price target of $878.00, representing a 10.5% upside. In a report issued on August 4, Oppenheimer also maintained a Buy rating on the stock with a $950.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on SUPN:
